Type II variation [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-06-22 13:12 (893 d 17:51 ago) – Posting: # 18948
Views: 5,709

Hi Beholder,

» […] whether we need to perform BEQ study in case of changes in amount of tablets in production batch or not? I refer to the table B.II.b.4 Change in the batch size (including batch size ranges) of the finished product

Yes because that’s a Type II (i.e., a major) variation. Only if the conditions for a bio­waiver are applicable you could get around an in vivo study.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,226 posts in 4,427 threads, 1,482 registered users;
online 9 (0 registered, 9 guests [including 3 identified bots]).
Forum time: Wednesday 07:04 UTC (Europe/Vienna)

A big data-analyst is an expert
in producing misleading conclusions from huge datasets.
It is much more efficient to use a statistician,
who can do the same with small ones.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5